Expand CORT Menu
CORT MENU

CORT Latest Press Releases

-- January 13, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT Globe Newswire 3:56 PM

-- January 12, 2026 --

CORT Investor ALERT: Corcept Therapeutics Inc. Investigated for Securities Fraud; Investors Should Contact Block & Leviton To Potentially Recover Losses Globe Newswire 11:54 AM

-- January 9, 2026 --

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT) Business Wire 10:00 AM

-- January 8, 2026 --

CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Incorporated on Behalf of Corcept Stockholders and Encourages Investors to Contact the Firm Globe Newswire 4:26 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT PRNewswire 10:00 AM
Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT) Globe Newswire 10:00 AM

-- January 7, 2026 --

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm Business Wire 8:03 PM
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman Globe Newswire 5:58 PM

-- January 6, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT Globe Newswire 12:53 PM
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman PRNewswire 12:01 PM

-- December 31, 2025 --

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism Business Wire 8:00 AM

-- November 4, 2025 --

Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update Business Wire 4:05 PM

-- October 28, 2025 --

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call Business Wire 4:05 PM

-- October 19, 2025 --

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment Business Wire 5:15 AM

-- October 14, 2025 --

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer Business Wire 8:00 AM

-- September 22, 2025 --

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025 Business Wire 2:30 PM

-- September 10, 2025 --

FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer Business Wire 8:00 AM
Market Data Delayed 15 Minutes